Key result
First-in-human Mitralign transcatheter tricuspid repair reduces annular area ~57% in a single patient.
Why the study?
Does transcatheter tricuspid valve repair using the Mitralign system improve annular area and hemodynamics in a patient with severe tricuspid regurgitation?
Population
1 high-surgical risk patient with severe tricuspid regurgitation non-responsive to optimal medical therapy
Design
Case_report
Authors
Loading...
Hypothesis-generating for transcatheter tricuspid repair; leaves open safety, durability, and outcomes in larger cohorts.
Case Report (n=1)
No
Does transcatheter tricuspid valve repair using the Mitralign system improve annular area and hemodynamics in a patient with severe tricuspid regurgitation?
First-in-human transcatheter tricuspid valve repair using the Mitralign system demonstrated feasibility and acute hemodynamic improvement in a patient with severe tricuspid regurgitation.
Schöfer et al. (2015) conducted a case report in Severe tricuspid regurgitation (n=1). Transcatheter tricuspid valve repair (Mitralign system) was evaluated on Feasibility of transcatheter tricuspid annular repair (reduction in annular area and effective regurgitant orifice area). First-in-human transcatheter tricuspid valve repair using the Mitralign system successfully reduced annular area by 57% and effective regurgitant orifice area by 53% in a single patient.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: